Drugs that contain Lenacapavir Sodium
1. List of Sunlenca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(10 years from now) | |
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(14 years from now) | |
| US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(14 years from now) | |
Do you want to check out SUNLENCA patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 22, 2027 |
NCE-1 date: 2026-12-22
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: TABLET;ORAL
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic